Literature DB >> 11889175

Functionally impaired TR mutants are present in thyroid papillary cancer.

Monika Puzianowska-Kuznicka1, Agnieszka Krystyniak, Agnieszka Madej, Sheue-Yann Cheng, Janusz Nauman.   

Abstract

TRs are transcription factors that regulate cell proliferation, differentiation, and apoptosis. They are cellular homologs of the transcriptionally inactive viral oncogene v-erbA. We tested the hypothesis that the functions of TRs could be impaired in cancer tissues as a result of aberrant expression and/or somatic mutations. As a model system, we selected human thyroid papillary cancer, in which the most common abnormalities, RET/papillary thyroid cancer rearrangements (fusion of RET kinase domain to the activating domains of other genes), were found in 40--45% of cases. We found that the mean expression levels of TR beta mRNA and TR alpha mRNA were significantly lower, whereas the protein levels of TR beta 1 and TR alpha 1 were higher in cancer tissues than in healthy thyroid. Sequencing of TR beta 1 and TR alpha 1 cDNAs, cloned from 16 papillary cancers, revealed that mutations affected receptor amino acid sequences in 93.75% and 62.5% of cases, respectively. In contrast, no mutations were found in healthy thyroid controls, and only 11.11% and 22.22% of thyroid adenomas had such TR beta 1 or TR alpha 1 mutations, respectively. The majority of the mutated TRs lost their trans-activation function and exhibited dominant negative activity. These findings suggest a possible role for mutated thyroid hormone receptors in the tumorigenesis of human papillary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889175     DOI: 10.1210/jcem.87.3.8296

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

3.  Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2009-04-30

4.  Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.

Authors:  F Rosignolo; V Maggisano; M Sponziello; M Celano; C R T Di Gioia; M D'Agostino; L Giacomelli; A Verrienti; M Dima; V Pecce; C Durante
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

Review 5.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

6.  A conserved lysine in the thyroid hormone receptor-alpha1 DNA-binding domain, mutated in hepatocellular carcinoma, serves as a sensor for transcriptional regulation.

Authors:  Ivan H Chan; Martin L Privalsky
Journal:  Mol Cancer Res       Date:  2010-01-06       Impact factor: 5.852

Review 7.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

Review 8.  Germline and somatic thyroid hormone receptor mutations in man.

Authors:  P M Yen; S Y Cheng
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

9.  Hypothyroidism enhances tumor invasiveness and metastasis development.

Authors:  Olaia Martínez-Iglesias; Susana García-Silva; Javier Regadera; Ana Aranda
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

10.  Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.